ECOG 0 4 0 4 B-clinical_variable
Performance 5 16 5 16 I-clinical_variable
Score 17 22 17 22 I-clinical_variable
must 23 27 23 27 O
be 28 30 28 30 O
≤ 31 32 31 32 O
2 33 34 33 34 B-upper_bound
within 35 41 35 41 O
two 42 45 42 45 B-upper_bound
weeks 46 51 46 51 I-upper_bound
prior 52 57 52 57 I-upper_bound
to 58 60 58 60 O
registration 61 73 61 73 O

Newly 0 5 74 79 O
diagnosed 6 15 80 89 O
, 15 16 89 90 O
untreated 17 26 91 100 O
intraocular 27 38 101 112 B-cancer
retinoblastoma 39 53 113 127 I-cancer
. 53 54 127 128 O
Participants 55 67 129 141 O
previously 68 78 142 152 O
diagnosed 79 88 153 162 O
with 89 93 163 167 O
unilateral 94 104 168 178 B-cancer
retinoblastoma 105 119 179 193 I-cancer
treated 120 127 194 201 O
surgically 128 138 202 212 O
, 138 139 212 213 O
with 140 144 214 218 O
focal 145 150 219 224 B-treatment
therapy 151 158 225 232 I-treatment
or 159 161 233 235 O
needing 162 169 236 243 O
chemotherapy 170 182 244 256 B-treatment
who 183 186 257 260 O
develop 187 194 261 268 O
asynchronous 195 207 269 281 O
involvement 208 219 282 293 O
of 220 222 294 296 O
the 223 226 297 300 O
contralateral 227 240 301 314 O
eye 241 244 315 318 O
, 244 245 318 319 O
or 246 248 320 322 O
patients 249 257 323 331 O
with 258 262 332 336 O
unilateral 263 273 337 347 O
retinoblastoma 274 288 348 362 O
treated 289 296 363 370 O
only 297 301 371 375 O
with 302 306 376 380 O
enucleation 307 318 381 392 B-treatment
or 319 321 393 395 O
focal 322 327 396 401 O
therapy 328 335 402 409 O
who 336 339 410 413 O
develop 340 347 414 421 O
asynchronous 348 360 422 434 O
involvement 361 372 435 446 O
of 373 375 447 449 O
the 376 379 450 453 O
contralateral 380 393 454 467 O
eye 394 397 468 471 O
, 397 398 471 472 O
will 399 403 473 477 O
be 404 406 478 480 O
eligible 407 415 481 489 O
for 416 419 490 493 O
study 420 425 494 499 O

Participants 0 12 500 512 O
must 13 17 513 517 O
have 18 22 518 522 O
adequate 23 31 523 531 B-chronic_disease
renal 32 37 532 537 I-chronic_disease
function 38 46 538 546 I-chronic_disease
as 47 49 547 549 O
defined 50 57 550 557 O
by 58 60 558 560 O
serum 61 66 561 566 B-clinical_variable
creatinine 67 77 567 577 I-clinical_variable
≤ 78 79 578 579 O
to 80 82 580 582 O
3X 83 85 583 585 B-upper_bound
ULN 86 89 586 589 I-upper_bound
for 90 93 590 593 O
age 94 97 594 597 B-age

Participants 0 12 598 610 O
must 13 17 611 615 O
have 18 22 616 620 O
an 23 25 621 623 O
adequate 26 34 624 632 O
liver 35 40 633 638 O
function 41 49 639 647 O
, 49 50 647 648 O
as 51 53 649 651 O
defined 54 61 652 659 O
by 62 64 660 662 O
bilirubin 65 74 663 672 B-clinical_variable
≤ 75 76 673 674 O
to 77 79 675 677 O
3X 80 82 678 680 B-upper_bound
upper 83 88 681 686 I-upper_bound
limit 89 94 687 692 I-upper_bound
of 95 97 693 695 I-upper_bound
normal 98 104 696 702 I-upper_bound
( 105 106 703 704 I-upper_bound
ULN 106 109 704 707 I-upper_bound
) 109 110 707 708 I-upper_bound
, 110 111 708 709 O
and 112 115 710 713 O
SGOT 116 120 714 718 B-clinical_variable
and 121 124 719 722 O
SGPT 125 129 723 727 B-clinical_variable
≤ 130 131 728 729 O
to 132 134 730 732 O
3X 135 137 733 735 B-upper_bound
ULN 138 141 736 739 I-upper_bound

Participants 0 12 740 752 O
must 13 17 753 757 O
not 18 21 758 761 O
have 22 26 762 766 O
an 27 29 767 769 O
invasive 30 38 770 778 B-chronic_disease
infection 39 48 779 788 I-chronic_disease
at 49 51 789 791 O
time 52 56 792 796 O
of 57 59 797 799 O
protocol 60 68 800 808 O
entry 69 74 809 814 O

Presence 0 8 815 823 O
of 9 11 824 826 O
metastatic 12 22 827 837 B-cancer
disease 23 30 838 845 I-cancer
or 31 33 846 848 O
gross 34 39 849 854 O
( 40 41 855 856 O
residual 41 49 856 864 O
) 49 50 864 865 O
orbital 51 58 866 873 O
involvement 59 70 874 885 O

